GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Capex-to-Operating-Income

Feng Chi Biotech (ROCO:6744) Capex-to-Operating-Income : 0.09 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Feng Chi Biotech's Capital Expenditure for the six months ended in Dec. 2023 was NT$-0.78 Mil. Its Operating Income for the six months ended in Dec. 2023 was NT$8.91 Mil.

Hence, Feng Chi Biotech's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.09.


Feng Chi Biotech Capex-to-Operating-Income Historical Data

The historical data trend for Feng Chi Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Capex-to-Operating-Income Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial 0.22 0.11 0.04 0.01 0.06

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.01 - 0.04 0.09

Competitive Comparison of Feng Chi Biotech's Capex-to-Operating-Income

For the Biotechnology subindustry, Feng Chi Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Feng Chi Biotech's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Feng Chi Biotech's Capex-to-Operating-Income falls into.



Feng Chi Biotech Capex-to-Operating-Income Calculation

Feng Chi Biotech's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.395) / 24.162
=0.06

Feng Chi Biotech's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.783) / 8.91
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Feng Chi Biotech  (ROCO:6744) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Feng Chi Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Feng Chi Biotech (ROCO:6744) Business Description

Traded in Other Exchanges
N/A
Address
No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech (ROCO:6744) Headlines

No Headlines